<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33667/2078-5631-2020-24-57-62</article-id><article-id custom-type="elpub" pub-id-type="custom">medalphabet-1788</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>В ПОМОЩЬ ПРАКТИЧЕСКОМУ ВРАЧУ</subject></subj-group></article-categories><title-group><article-title>Поддерживающая терапия акне: профилактическая эффективность фиксированной комбинации адапалена и бензоила пероксида</article-title><trans-title-group xml:lang="en"><trans-title>Maintenance acne therapy: prophylactic efficacy of fixed combination of adapalene and benzoyl peroxide</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Круглова</surname><given-names>Л. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kruglova</surname><given-names>L. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., проф., проректор по учебной работе, зав. кафедрой дерматовенерологии и косметологии,</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Грязева</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gryazeva</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., доцент кафедры дерматовенерологии и косметологии,</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Central State Medical Academy of the Administrative Department of the President of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>18</day><month>12</month><year>2020</year></pub-date><volume>0</volume><issue>24</issue><issue-title>Дерматология (2)</issue-title><fpage>57</fpage><lpage>62</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Круглова Л.С., Грязева Н.В., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Круглова Л.С., Грязева Н.В.</copyright-holder><copyright-holder xml:lang="en">Kruglova L.S., Gryazeva N.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/1788">https://www.med-alphabet.com/jour/article/view/1788</self-uri><abstract><p>Акне является хроническим заболеванием, и даже надежные методы терапии полностью не обеспечивают отсутствие рецидивов. Рецидивы акне оказывают негативное психологическое воздействие на пациентов, так как они чувствуют себя неспособными контролировать болезнь и добиться полного и стойкого выздоровления. Поддерживающая терапия необходима для пролонгации ремиссии акне, достигнутой при первоначальном успешном лечении, и минимизации риска рецидива. Наиболее обоснованным в качестве поддерживающей терапии, по данным литературы, является использование топических ретиноидов, которые показали эффективность в отношении профилактики обострений акне. В настоящем исследовании участвовали 54 пациента, которые после активной терапии в качестве поддерживающего лечения использовали фиксированную комбинацию адапалена 0,1% и БПО 2,5%. Только у 1 (2,9%) пациента с акне средней степени тяжести и у 2 (5,8%) пациентов с акне тяжелой степени наблюдался рецидив в течение 6 месяцев поддерживающей терапии. Зафиксировано отсутствие нежелательных явлений в процессе лечения, а также высокая приверженность пациентов к лечению. В период активного наблюдения (6 месяцев после поддерживающей терапии) из числа пациентов без обострения в период поддерживающей терапии рецидив наступил у 2 (7,1%) пациентов первой группы (n = 28) и 2 (8,7%) пациентов – второй (n = 23). Полученные данные свидетельствуют о том, что поддерживающая терапия гелем Эффезел® может продлить достигнутую эффективность лечения и предупредить развитие рецидива.</p></abstract><trans-abstract xml:lang="en"><p>Acne is a chronic disease and even reliable therapies do not completely ensure absence of relapses. Acne relapses have a negative psychological impact on patients, as they feel unable to control the disease and achieve complete and long-lasting recovery. Supportive therapy is necessary to prolong the remission of acne achieved with initial successful treatment and to minimize the risk of relapse. According to the literature sources, the most justified as a maintenance therapy is the use of topical retinoids, which have been shown to be effective in the prevention of exacerbations of acne. In the present study 54 patients were involved who after the active therapy used a fixed combination of adapalene 0.1% / BPO 2.5% as maintenance treatment. Only 1 patient (2.9%) with moderate acne and 2 patients (5.8%) with severe acne had a relapse within 6 months of maintenance therapy. The absence of adverse events during the course of treatment was recorded, as well as high adherence of patients to the treatment. During the period of post-treatment observation (6 months after maintenance therapy), among the patients without exacerbations during maintenance therapy, a relapse occurred in 2 (7.1%) patients of group 1 (n = 28) and 2 (8.7%) patients of group 2 (n = 23). The obtained data indicates that maintenance therapy with Effezel® gel can extend the achieved effectiveness of the treatment and prevent the development of relapses.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>акне</kwd><kwd>поддерживающая терапия</kwd><kwd>фиксированная комбинация адапалена 0</kwd><kwd>1% и БПО 2</kwd><kwd>5%</kwd></kwd-group><kwd-group xml:lang="en"><kwd>acne</kwd><kwd>maintenance therapy</kwd><kwd>fixed combination adapalene 0.1% and BPO 2.5%</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Thiboutot D, Gollnick H, Bettoli V, Dréno B, Kang S, Leyden JJ, Shalita AR, Lozada VT, Berson D, Finlay A, Goh CL, Herane MI, Kaminsky A, Kubba R, Layton A, Miyachi Y, Perez M, Martin JP, Ramos-E-Silva M, See JA, Shear N, Wolf J Jr. Global Alliance to Improve Outcomes in Acne: New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009; 60 (5 suppl): S1–S50.</mixed-citation><mixed-citation xml:lang="en">Thiboutot D, Gollnick H, Bettoli V, Dréno B, Kang S, Leyden JJ, Shalita AR, Lozada VT, Berson D, Finlay A, Goh CL, Herane MI, Kaminsky A, Kubba R, Layton A, Miyachi Y, Perez M, Martin JP, Ramos-E-Silva M, See JA, Shear N, Wolf J Jr. Global Alliance to Improve Outcomes in Acne: New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009; 60 (5 suppl): S1–S50.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Zane L. Acne maintenance therapy: expanding the role of topical retinoids? Arch Dermatol 2006; 142: 638–640.</mixed-citation><mixed-citation xml:lang="en">Zane L. Acne maintenance therapy: expanding the role of topical retinoids? Arch Dermatol 2006; 142: 638–640.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Thielitz A, Helmdach M, Röpke EM, Gollnick H. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br J Dermatol 2001; 145: 19–27.</mixed-citation><mixed-citation xml:lang="en">Thielitz A, Helmdach M, Röpke EM, Gollnick H. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br J Dermatol 2001; 145: 19–27.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Schmidt N, Gans EH. Tretinoin: a review of its anti-inflammatory properties in the treatment of acne. J Clin Aesthet Dermatol 2011; 4: 22–29.</mixed-citation><mixed-citation xml:lang="en">Schmidt N, Gans EH. Tretinoin: a review of its anti-inflammatory properties in the treatment of acne. J Clin Aesthet Dermatol 2011; 4: 22–29.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kang S. The mechanism of action of topical retinoids. Cutis 2005; 75: 10–13.</mixed-citation><mixed-citation xml:lang="en">Kang S. The mechanism of action of topical retinoids. Cutis 2005; 75: 10–13.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Gollnick H, Cunliffe WJ, Berson D, Dreno B, Finlay A, Leyden JJ, Shalita AR, Thiboutot D. Global Alliance to Improve Outcomes in Acne: Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49 (1 suppl): S1–S37.</mixed-citation><mixed-citation xml:lang="en">Gollnick H, Cunliffe WJ, Berson D, Dreno B, Finlay A, Leyden JJ, Shalita AR, Thiboutot D. Global Alliance to Improve Outcomes in Acne: Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49 (1 suppl): S1–S37.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Cunliffe W, Gollnick H. Acne – Diagnosis and Management. London, Martin Dunitz, 2001. Journal of the Royal Society of Medicine 94 (12): 652–652.</mixed-citation><mixed-citation xml:lang="en">Cunliffe W, Gollnick H. Acne – Diagnosis and Management. London, Martin Dunitz, 2001. Journal of the Royal Society of Medicine 94 (12): 652–652.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zouboulis CC. The truth behind this undeniable efficacy – recurrence rates and relapse risk factors of acne treatment with oral isotretinoin. Dermatology 2006; 212: 99–100.</mixed-citation><mixed-citation xml:lang="en">Zouboulis CC. The truth behind this undeniable efficacy – recurrence rates and relapse risk factors of acne treatment with oral isotretinoin. Dermatology 2006; 212: 99–100.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang JZ, Li LF, Tu YT, Zheng JJ. A successful maintenance approach in inflammatory acne with adapalene gel 0.1% after an initial treatment in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1%. J Dermatolog Treat 2004; 15: 372–378.</mixed-citation><mixed-citation xml:lang="en">Zhang JZ, Li LF, Tu YT, Zheng JJ. A successful maintenance approach in inflammatory acne with adapalene gel 0.1% after an initial treatment in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1%. J Dermatolog Treat 2004; 15: 372–378.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Thielitz A, Sidou F, Gollnick H. Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%. J Eur Acad Dermatol Venereol. 2007; 21: 747–753.</mixed-citation><mixed-citation xml:lang="en">Thielitz A, Sidou F, Gollnick H. Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%. J Eur Acad Dermatol Venereol. 2007; 21: 747–753.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Kerrouche N, Arsonnaud S, Kang S. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol. 2006; 142: 597–602.</mixed-citation><mixed-citation xml:lang="en">Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Kerrouche N, Arsonnaud S, Kang S. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol. 2006; 142: 597–602.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Alirezai M, George SA, Coutts I, Roseeuw DI, Hachem JP, Kerrouche N, Sidou F, Soto P. Daily treatment with adapalene gel 0.1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline. Eur J Dermatol. 2007; 17: 45–51.</mixed-citation><mixed-citation xml:lang="en">Alirezai M, George SA, Coutts I, Roseeuw DI, Hachem JP, Kerrouche N, Sidou F, Soto P. Daily treatment with adapalene gel 0.1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline. Eur J Dermatol. 2007; 17: 45–51.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Cassano N, Amoruso A, Alessandrini G, Biuso A, Carrieri G, Fai D, Gabellone M, Ligori P, Malvindi C, Mancino A. Treatment of inflammatory acne with a combination therapy with lymecycline and adapalene followed by maintenance treatment with adapalene. Eur J Inflamm. 2004; 2: 45–52.</mixed-citation><mixed-citation xml:lang="en">Cassano N, Amoruso A, Alessandrini G, Biuso A, Carrieri G, Fai D, Gabellone M, Ligori P, Malvindi C, Mancino A. Treatment of inflammatory acne with a combination therapy with lymecycline and adapalene followed by maintenance treatment with adapalene. Eur J Inflamm. 2004; 2: 45–52.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Leyden J, Thiboutot DM, Shalita AR, Webster G, Washenik K, Strober BE, Shupack J. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel group study. Arch Dermatol. 2006; 142: 605–612.</mixed-citation><mixed-citation xml:lang="en">Leyden J, Thiboutot DM, Shalita AR, Webster G, Washenik K, Strober BE, Shupack J. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel group study. Arch Dermatol. 2006; 142: 605–612.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Vender R, Vender R. Double-blinded, vehicle-controlled proof of concept study to investigate the recurrence of inflammatory and noninflammatory acne lesions using tretinoin gel (microsphere) 0.04% in male patients after oral isotretinoin use. Dermatol Res Pract. Volume 2012 Article ID736532.</mixed-citation><mixed-citation xml:lang="en">Vender R, Vender R. Double-blinded, vehicle-controlled proof of concept study to investigate the recurrence of inflammatory and noninflammatory acne lesions using tretinoin gel (microsphere) 0.04% in male patients after oral isotretinoin use. Dermatol Res Pract. Volume 2012 Article ID736532.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Gollnick HP, Graupe K, Zaumseil RP. Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne. Eur J Dermatol 2001; 11: 538–544.</mixed-citation><mixed-citation xml:lang="en">Gollnick HP, Graupe K, Zaumseil RP. Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne. Eur J Dermatol 2001; 11: 538–544.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Poulin Y, Sanchez NP, Bucko A, Fowler J, Jarratt M, Kempers S, Kerrouche N, Dhuin JC, Kunynetz R. A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial. Br J Dermatol 2011; 164: 1376–1382.</mixed-citation><mixed-citation xml:lang="en">Poulin Y, Sanchez NP, Bucko A, Fowler J, Jarratt M, Kempers S, Kerrouche N, Dhuin JC, Kunynetz R. A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial. Br J Dermatol 2011; 164: 1376–1382.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Bettoli V, Mantovani L, Borghi A. Adapalene 0.1% cream after oral isotretinoin: evaluation of acne recurrence incidence. Rhodes: Medimond Monduzzi Editore International Proceedings, Division 15th Congress of the European Academy of Dermatology and Venereology, 2006; 212: 206–715.</mixed-citation><mixed-citation xml:lang="en">Bettoli V, Mantovani L, Borghi A. Adapalene 0.1% cream after oral isotretinoin: evaluation of acne recurrence incidence. Rhodes: Medimond Monduzzi Editore International Proceedings, Division 15th Congress of the European Academy of Dermatology and Venereology, 2006; 212: 206–715.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Borghi A, Mantovani L, Minghetti S, Giari S, Virgili A, Bettoli V. Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission. J Eur Acad Dermatol Venereol 2011; 25: 1094–1098.</mixed-citation><mixed-citation xml:lang="en">Borghi A, Mantovani L, Minghetti S, Giari S, Virgili A, Bettoli V. Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission. J Eur Acad Dermatol Venereol 2011; 25: 1094–1098.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
